ClinicalTrials.gg
CompletedNCT05900154PICASSOUpdated Mar 6, 2025Results posted

A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age

A Phase 1 interventional study of RSVpreF 120 µg and RSVpreF 60 µg in RESPIRATORY SYNCYTIAL VIRUS (RSV), sponsored by Pfizer. Completed at 17 sites in United States. Open to participants aged 2 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-06.

Sponsored by Pfizer · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Respiratory Tract Infections by Pfizer — 2 open to participants now, 3 under way, 2 of them phase 3. Respiratory Tract Infections · Pfizer.

Enrollment
12th of 18
128 · median 309
Started
2023
the only one that year
Phase 1
4 of 23
none open now
Registered
16th of 23
by date

Among the 23 studies in Respiratory Tract Infections by Pfizer, this one is the 12th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2023, is one of 4 in phase 1, and was the 16th registered.

Respiratory Tract Infections

753 studies on the registry are indexed under Respiratory Tract Infections; 114 are open to participants now.

Browse Respiratory Tract Infections studies →

Open to participants now

2 of the 23 studies in Respiratory Tract Infections by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 74 Respiratory Tract Infections studies recruiting now, 35 (47%) set no upper age limit and 31 (42%) stop at 75 or younger; 34 take children under 18; 25 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Respiratory Tract Infections by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the safety and immune activity of the vaccine (called RSVpreF) in children 2 to \<18 years of age.

This study will identify the dose level to be used in Phase 2/3 trials in this age cohort. All participants will receive one injection of RSVpreF. This study has four study visits, two in-clinic and two telehealth visits. Blood samples will be collected for testing. This study is about 6 months long for each participant and will be conducted in the United States.

03

Conditions studied

  • RESPIRATORY SYNCYTIAL VIRUS (RSV)

Keywords

  • RESPIRATORY SYNCYTIAL VIRUS
  • RSV
  • RSV vaccine
  • Respiratory illness
  • Respiratory infection
  • Pediatric
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants 2 to \<18 years of age at enrollment
  2. Participants 2 to \<18 years of age should either be healthy or be considered by the investigator to be at high risk of RSV disease based on the presence of 1 of the following chronic medical conditions:

    • Cystic fibrosis
    • Medically treated asthma
    • Other chronic respiratory diseases and malformations of the lung
    • Down syndrome
    • Neuromuscular disease
    • Cerebral palsy
    • Hemodynamically significant or symptomatic congenital heart disease
  3. All participants 2 to \<5 years of age must be seropositive for RSV as confirmed by serology.
  4. Participants' parent(s)/legal guardian(s) and participants, as age appropriate, who are willing and able to comply with all scheduled visits, plan, laboratory tests, and other study procedures, including collection of nasal swabs by participants' parent(s)/legal guardian(s) and by study staff when indicated.
  5. The participant's parent(s)/legal guardian is capable of giving signed as described in the protocol. Depending on the age of the participant and according to local requirements, participants will also be asked to provide assent as appropriate (verbal or written).

Exclusion criteria

Exclusion Criteria:

  1. individuals associated with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
  2. Individuals with a history of disease or an active autoimmune disease requiring therapeutic intervention, including but not limited to systemic lupus erythematosus. Note: Stable type 1 diabetes and hypothyroidism are permitted.
  3. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  4. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s).
  5. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  6. Individuals with a history of epilepsy or other seizure disorders, or a history of seizures and/or other neurological complications following vaccination.
  7. Previous vaccination with any licensed or RSV vaccine or planned receipt during study participation. Children who may have been exposed to investigational RSV vaccines through maternal immunization will be permitted.
  8. Receipt of investigational or approved monoclonal antibodies against RSV within 6 months before study intervention administration, or planned receipt throughout the study.
  9. Receipt of blood/plasma products or immunoglobulins within 28 days before study intervention administration, or planned receipt throughout the study.
  10. Receipt of chronic systemic treatment with known immunosuppressant medications (including cytotoxic agents or systemic ), or radiotherapy, within 60 days before study intervention administration, or planned receipt throughout the study.

    Note: Systemic corticosteroids are defined as those administered for ≥14 days at a dose of ≥20 mg/day of prednisone or equivalent (eg, for cancer or an autoimmune disease). Inhaled/nebulized, intra-articular, intrabursal, or topical (skin, eyes, or ears) corticosteroids are permitted.

  11. Participation in other studies involving study intervention within 28 days prior to study entry and/or for the duration of study participation.
  12. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
128 participants (actual)

Study arms

  • Experimental
    standard dose in 5 to <18 years olds, healthy

    standard dose (120 µg)

    Biological: RSVpreF 120 µg

  • Experimental
    standard dose in 5 to < 18 years olds, with chronic high risk conditions

    standard dose (120 µg)

    Biological: RSVpreF 120 µg

  • Experimental
    standard dose in 2 to < 5 years olds

    standard dose (120 µg)

    Biological: RSVpreF 120 µg

  • Experimental
    low dose in 5 to <18 years olds, healthy

    low dose (60 µg)

    Biological: RSVpreF 60 µg

  • Experimental
    low dose in 5 to <18 years olds, with chronic high risk conditions

    low dose (60 µg)

    Biological: RSVpreF 60 µg

  • Experimental
    low dose in 2 to < 5 years olds

    low dose (60 µg)

    Biological: RSVpreF 60 µg

Interventions

  • BiologicalRSVpreF 120 µg

    RSVpreF standard dose level

  • BiologicalRSVpreF 60 µg

    RSVpreF low dose level

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Local Reactions Within 7 Days After Vaccination

    Local reactions were collected in the electronic diary (e-diary) from Day 1 through Day 7 after vaccination. Local reactions included pain at injection site, redness, and swelling. For participants greater than or equal to (\>=) 2 years to \<12 years of age, redness and swelling were graded as mild: 0.5 to 2.0 centimeter (cm), moderate: \>2.0 to 7.0 cm, and severe: \> 7 cm; for participants \>=12 years of age, mild: \> 2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm, and severe: \>10 cm. Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).

    Time frame: Day 1 through Day 7 after Vaccination

  2. Percentage of Participants With Systemic Events Within 7 Days After Vaccination

    Systemic events included fever, fatigue, headache, vomiting, diarrhea, muscle pain and joint pain and were recorded by participants using e-diary. Fever: oral temperature \>= 38.0 degree Celsius (deg C) and categorized as \>=38.0 to 38.4 deg C (mild), \>38.4 to 38.9 deg C (moderate), and \>38.9 to 40.0 deg C (severe). Fatigue, headache, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity), and severe (prevented daily routine activity). Vomiting was graded mild: 1-2 times in 24 hours (h), moderate: \>2 times in 24h, and severe: required intravenous hydration. Diarrhea was graded mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h and severe: 6 or more loose stools in 24h.

    Time frame: Day 1 through Day 7 after Vaccination

  3. Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination

    AE was defined as any untoward medical occurrence in clinical study participant, temporally associated with use of study intervention, whether or not considered related to study intervention. AEs included serious and all non-serious AE. SAEs were defined as AE that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was congenital anomaly or birth defect; was suspected transmission via Pfizer product of infectious agent, pathogenic or nonpathogenic or was considered to be an important medical event. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were included.

    Time frame: Within 1 month post Vaccination

  4. Percentage of Participants With Serious Adverse Events (SAEs) Throughout the Study

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAEs were defined as an AE that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability or incapacity; was a congenital anomaly or birth defect; was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or nonpathogenic or that was considered to be an important medical event.

    Time frame: Within 6 months post Vaccination

  5. Percentage of Participants Reporting Newly Diagnosed Chronic Medical Condition (NDCMCs) Throughout the Study

    An NDCMC was defined as a disease or medical condition, which was not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: Within 6 months post Vaccination

Secondary outcomes

  1. Geometric Mean Titer of the Neutralizing Titers for RSV A and RSV B Before Vaccination and 1 Month After Vaccination

    Geometric mean titer (GMT) of neutralizing titers (NTs) of respiratory syncytial virus subgroup A and respiratory syncytial virus subgroup B (RSV A and RSV B) before vaccination and 1 month after vaccination were reported in this outcome measure. Assay results below the lower limit of quantification (LLOQ) were set to 0.5\*LLOQ. GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution).

    Time frame: Before vaccination and 1 month after vaccination

  2. Geometric Mean Fold Rise (GMFR) of the NTs for RSV A and RSV B From Before Vaccination to 1 Month After Vaccination

    GMFR of neutralizing titers of RSV A and RSV B from before vaccination to 1 month after vaccination were reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding CIs (based on the Student's t distribution).

    Time frame: From before vaccination to 1 month after vaccination

  3. Median Frequencies of RSV F Antigen-Specific Cluster of Differentiation 4 (CD4+) Thymus-Derived Lymphocytes (T) Cells Expressing Interferon (IFN) Gamma and Interleukin-4 (IL-4) Before Vaccination and 1 Month After Vaccination

    Median frequencies of RSV F antigen-specific CD4+ T cells expressing IFN gamma and IL-4 before vaccination and 1 month after vaccination were reported in this outcome measure. RSV F enzyme-linked immune absorbent spot assay (ELISpot) limit of detection (LOD) values were IFN gamma = 20 spot forming cell (SFC) per million peripheral blood mononuclear cell (PBMCs) and IL-4 = 4 SFC/million PBMCs. Assay results below LOD=0.5\*LOD for analysis. Frequencies were defined as the count of the RSV F antigen-specific CD4+ T cells and median frequencies were defined as the median of the counts.

    Time frame: Before vaccination and 1 Month after vaccination

07

Results

Posted Mar 6, 2025

Participant flow

A total of 128 participants were enrolled, however 1 participant was assigned to a vaccine group but did not receive vaccination. Consequently, a total of 127 participants were vaccinated.

Vaccination Period
Participant flow — Vaccination Period
MilestoneRSVpreF 120 Micrograms (mcg): 5 to <18 Years [Healthy Participants]RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 120 mcg: 2 to < 5 YearsRSVpreF 60 mcg: 5 to <18 Years [Healthy Participants]RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 60 mcg: 2 to < 5 Years
Started252324171820
Completed252324171820
Not completed000000
Follow-Up Period
Participant flow — Follow-Up Period
MilestoneRSVpreF 120 Micrograms (mcg): 5 to <18 Years [Healthy Participants]RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 120 mcg: 2 to < 5 YearsRSVpreF 60 mcg: 5 to <18 Years [Healthy Participants]RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 60 mcg: 2 to < 5 Years
Started252324171820
Completed242123171719
Not completed121011
Withdrew: Lost to follow-up121011

Outcome measures

PrimaryPercentage of Participants With Local Reactions Within 7 Days After Vaccination

Local reactions were collected in the electronic diary (e-diary) from Day 1 through Day 7 after vaccination. Local reactions included pain at injection site, redness, and swelling. For participants greater than or equal to (\>=) 2 years to \<12 years of age, redness and swelling were graded as mild: 0.5 to 2.0 centimeter (cm), moderate: \>2.0 to 7.0 cm, and severe: \> 7 cm; for participants \>=12 years of age, mild: \> 2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm, and severe: \>10 cm. Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).

Time frame:
Day 1 through Day 7 after Vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Vaccination
Percentage of participantsRSVpreF 120 mcg: 5 to <18 Years [Healthy Participants]RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 120 mcg: 2 to <5 YearsRSVpreF 60 mcg: 5 to <18 Years [Healthy Participants]RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 60 mcg: 2 to <5 Years
Pain at injection site: Mild36.0 (18.0 to 57.5)39.1 (19.7 to 61.5)8.3 (1.0 to 27.0)35.3 (14.2 to 61.7)33.3 (13.3 to 59.0)15.0 (3.2 to 37.9)
Pain at injection site: Moderate8.0 (1.0 to 26.0)8.7 (1.1 to 28.0)0 (0.0 to 14.2)5.9 (0.1 to 28.7)22.2 (6.4 to 47.6)0 (0.0 to 16.8)
Pain at injection site: Severe4.0 (0.1 to 20.4)0 (0.0 to 14.8)0 (0.0 to 14.2)0 (0.0 to 19.5)0 (0.0 to 18.5)0 (0.0 to 16.8)
Redness: Mild12.0 (2.5 to 31.2)4.3 (0.1 to 21.9)12.5 (2.7 to 32.4)0 (0.0 to 19.5)11.1 (1.4 to 34.7)5.0 (0.1 to 24.9)
Redness: Moderate12.0 (2.5 to 31.2)4.3 (0.1 to 21.9)0 (0.0 to 14.2)5.9 (0.1 to 28.7)0 (0.0 to 18.5)0 (0.0 to 16.8)
Redness: Severe0 (0.0 to 13.7)0 (0.0 to 14.8)0 (0.0 to 14.2)0 (0.0 to 19.5)0 (0.0 to 18.5)0 (0.0 to 16.8)
Swelling: Mild4.0 (0.1 to 20.4)0 (0.0 to 14.8)4.2 (0.1 to 21.1)0 (0.0 to 19.5)11.1 (1.4 to 34.7)0 (0.0 to 16.8)
Swelling: Moderate8.0 (1.0 to 26.0)8.7 (1.1 to 28.0)0 (0.0 to 14.2)5.9 (0.1 to 28.7)11.1 (1.4 to 34.7)5.0 (0.1 to 24.9)
Swelling: Severe0 (0.0 to 13.7)0 (0.0 to 14.8)0 (0.0 to 14.2)0 (0.0 to 19.5)0 (0.0 to 18.5)0 (0.0 to 16.8)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Vaccination

Systemic events included fever, fatigue, headache, vomiting, diarrhea, muscle pain and joint pain and were recorded by participants using e-diary. Fever: oral temperature \>= 38.0 degree Celsius (deg C) and categorized as \>=38.0 to 38.4 deg C (mild), \>38.4 to 38.9 deg C (moderate), and \>38.9 to 40.0 deg C (severe). Fatigue, headache, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity), and severe (prevented daily routine activity). Vomiting was graded mild: 1-2 times in 24 hours (h), moderate: \>2 times in 24h, and severe: required intravenous hydration. Diarrhea was graded mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h and severe: 6 or more loose stools in 24h.

Time frame:
Day 1 through Day 7 after Vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Vaccination
Percentage of participantsRSVpreF 120 mcg: 5 to <18 Years [Healthy Participants]RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 120 mcg: 2 to <5 YearsRSVpreF 60 mcg: 5 to <18 Years [Healthy Participants]RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 60 mcg: 2 to < 5 Years
Fever: Mild0 (0.0 to 13.7)4.3 (0.1 to 21.9)4.2 (0.1 to 21.1)0 (0.0 to 19.5)0 (0.0 to 18.5)5.0 (0.1 to 24.9)
Fever: Moderate0 (0.0 to 13.7)0 (0.0 to 14.8)0 (0.0 to 14.2)0 (0.0 to 19.5)5.6 (0.1 to 27.3)0 (0.0 to 16.8)
Fever: Severe0 (0.0 to 13.7)0 (0.0 to 14.8)0 (0.0 to 14.2)5.9 (0.1 to 28.7)5.6 (0.1 to 27.3)0 (0.0 to 16.8)
Fatigue: Mild20.0 (6.8 to 40.7)21.7 (7.5 to 43.7)20.8 (7.1 to 42.2)41.2 (18.4 to 67.1)16.7 (3.6 to 41.4)30.0 (11.9 to 54.3)
Fatigue: Moderate12.0 (2.5 to 31.2)21.7 (7.5 to 43.7)8.3 (1.0 to 27.0)5.9 (0.1 to 28.7)33.3 (13.3 to 59.0)5.0 (0.1 to 24.9)
Fatigue: Severe0 (0.0 to 13.7)0 (0.0 to 14.8)0 (0.0 to 14.2)0 (0.0 to 19.5)0 (0.0 to 18.5)0 (0.0 to 16.8)
Headache: Mild16.0 (4.5 to 36.1)26.1 (10.2 to 48.4)0 (0.0 to 14.2)29.4 (10.3 to 56.0)16.7 (3.6 to 41.4)0 (0.0 to 16.8)
Headache: Moderate12.0 (2.5 to 31.2)8.7 (1.1 to 28.0)4.2 (0.1 to 21.1)11.8 (1.5 to 36.4)16.7 (3.6 to 41.4)0 (0.0 to 16.8)
Headache: Severe0 (0.0 to 13.7)0 (0.0 to 14.8)0 (0.0 to 14.2)0 (0.0 to 19.5)0 (0.0 to 18.5)0 (0.0 to 16.8)
Muscle pain: Mild16.0 (4.5 to 36.1)21.7 (7.5 to 43.7)0 (0.0 to 14.2)23.5 (6.8 to 49.9)33.3 (13.3 to 59.0)0 (0.0 to 16.8)
Muscle pain: Moderate4.0 (0.1 to 20.4)17.4 (5.0 to 38.8)0 (0.0 to 14.2)0 (0.0 to 19.5)5.6 (0.1 to 27.3)0 (0.0 to 16.8)
Muscle pain: Severe0 (0.0 to 13.7)0 (0.0 to 14.8)0 (0.0 to 14.2)0 (0.0 to 19.5)0 (0.0 to 18.5)0 (0.0 to 16.8)
Joint pain: Mild4.0 (0.1 to 20.4)4.3 (0.1 to 21.9)0 (0.0 to 14.2)0 (0.0 to 19.5)11.1 (1.4 to 34.7)0 (0.0 to 16.8)
Joint pain: Moderate4.0 (0.1 to 20.4)0 (0.0 to 14.8)0 (0.0 to 14.2)0 (0.0 to 19.5)0 (0.0 to 18.5)0 (0.0 to 16.8)
Joint pain: Severe0 (0.0 to 13.7)0 (0.0 to 14.8)0 (0.0 to 14.2)0 (0.0 to 19.5)0 (0.0 to 18.5)0 (0.0 to 16.8)
Vomiting: Mild0 (0.0 to 13.7)0 (0.0 to 14.8)0 (0.0 to 14.2)5.9 (0.1 to 28.7)5.6 (0.1 to 27.3)10.0 (1.2 to 31.7)
Vomiting: Moderate0 (0.0 to 13.7)0 (0.0 to 14.8)0 (0.0 to 14.2)0 (0.0 to 19.5)0 (0.0 to 18.5)0 (0.0 to 16.8)
Vomiting: Severe0 (0.0 to 13.7)0 (0.0 to 14.8)0 (0.0 to 14.2)0 (0.0 to 19.5)0 (0.0 to 18.5)0 (0.0 to 16.8)
Diarrhea: Mild4.0 (0.1 to 20.4)8.7 (1.1 to 28.0)4.2 (0.1 to 21.1)0 (0.0 to 19.5)5.6 (0.1 to 27.3)0 (0.0 to 16.8)
Diarrhea: Moderate0 (0.0 to 13.7)0 (0.0 to 14.8)8.3 (1.0 to 27.0)0 (0.0 to 19.5)0 (0.0 to 18.5)0 (0.0 to 16.8)
Diarrhea: Severe0 (0.0 to 13.7)0 (0.0 to 14.8)0 (0.0 to 14.2)0 (0.0 to 19.5)0 (0.0 to 18.5)0 (0.0 to 16.8)
PrimaryPercentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination

AE was defined as any untoward medical occurrence in clinical study participant, temporally associated with use of study intervention, whether or not considered related to study intervention. AEs included serious and all non-serious AE. SAEs were defined as AE that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was congenital anomaly or birth defect; was suspected transmission via Pfizer product of infectious agent, pathogenic or nonpathogenic or was considered to be an important medical event. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were included.

Time frame:
Within 1 month post Vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination
Percentage of participantsRSVpreF 120 mcg: 5 to <18 Years [Healthy Participants]RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 120 mcg: 2 to <5 YearsRSVpreF 60 mcg: 5 to <18 Years [Healthy Participants]RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 60 mcg: 2 to <5 Years
Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination0 (0.0 to 13.7)17.4 (5.0 to 38.8)12.5 (2.7 to 32.4)0 (0.0 to 19.5)27.8 (9.7 to 53.5)15.0 (3.2 to 37.9)
PrimaryPercentage of Participants With Serious Adverse Events (SAEs) Throughout the Study

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAEs were defined as an AE that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability or incapacity; was a congenital anomaly or birth defect; was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or nonpathogenic or that was considered to be an important medical event.

Time frame:
Within 6 months post Vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs) Throughout the Study
Percentage of participantsRSVpreF 120 mcg: 5 to <18 Years [Healthy Participants]RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 120 mcg: 2 to <5 YearsRSVpreF 60 mcg: 5 to <18 Years [Healthy Participants]RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 60 mcg: 2 to <5 Years
Percentage of Participants With Serious Adverse Events (SAEs) Throughout the Study0 (0.0 to 13.7)4.3 (0.1 to 21.9)0 (0.0 to 14.2)0 (0.0 to 19.5)5.6 (0.1 to 27.3)0 (0.0 to 16.8)
PrimaryPercentage of Participants Reporting Newly Diagnosed Chronic Medical Condition (NDCMCs) Throughout the Study

An NDCMC was defined as a disease or medical condition, which was not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
Within 6 months post Vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Newly Diagnosed Chronic Medical Condition (NDCMCs) Throughout the Study
Percentage of participantsRSVpreF 120 mcg: 5 to <18 Years [Healthy Participants]RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 120 mcg: 2 to <5 YearsRSVpreF 60 mcg: 5 to <18 Years [Healthy Participants]RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 60 mcg: 2 to <5 Years
Percentage of Participants Reporting Newly Diagnosed Chronic Medical Condition (NDCMCs) Throughout the Study0 (0.0 to 13.7)0 (0.0 to 14.8)0 (0.0 to 14.2)0 (0.0 to 19.5)0 (0.0 to 18.5)0 (0.0 to 16.8)
SecondaryGeometric Mean Titer of the Neutralizing Titers for RSV A and RSV B Before Vaccination and 1 Month After Vaccination

Geometric mean titer (GMT) of neutralizing titers (NTs) of respiratory syncytial virus subgroup A and respiratory syncytial virus subgroup B (RSV A and RSV B) before vaccination and 1 month after vaccination were reported in this outcome measure. Assay results below the lower limit of quantification (LLOQ) were set to 0.5\*LLOQ. GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution).

Time frame:
Before vaccination and 1 month after vaccination
Reported as:
Geometric mean · Titer
Geometric Mean Titer of the Neutralizing Titers for RSV A and RSV B Before Vaccination and 1 Month After Vaccination
TiterRSVpreF 120 mcg: 5 to <18 Years [Healthy Participants]RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 120 mcg: 2 to <5 YearsRSVpreF 60 mcg: 5 to <18 Years [Healthy Participants]RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 60 mcg: 2 to <5 Years
RSV A: Before vaccination1168 (706 to 1932)2003 (1421 to 2823)529 (335 to 835)916 (653 to 1285)1667 (1035 to 2684)561 (309 to 1016)
RSV A:1 Month after vaccination27862 (21493 to 36119)35503 (26876 to 46900)26146 (13301 to 51396)25341 (15394 to 41715)24053 (17440 to 33173)11004 (4287 to 28245)
RSV B: Before vaccination1206 (717 to 2027)1905 (1238 to 2930)391 (231 to 661)965 (668 to 1393)1760 (947 to 3272)499 (258 to 967)
RSV B:1 Month after vaccination30251 (21607 to 42355)29019 (18786 to 44827)16504 (8267 to 32948)33351 (23565 to 47202)31174 (21756 to 44668)10659 (3526 to 32228)
SecondaryGeometric Mean Fold Rise (GMFR) of the NTs for RSV A and RSV B From Before Vaccination to 1 Month After Vaccination

GMFR of neutralizing titers of RSV A and RSV B from before vaccination to 1 month after vaccination were reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding CIs (based on the Student's t distribution).

Time frame:
From before vaccination to 1 month after vaccination
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rise (GMFR) of the NTs for RSV A and RSV B From Before Vaccination to 1 Month After Vaccination
Fold riseRSVpreF 120 mcg: 5 to <18 Years [Healthy Participants]RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 120 mcg: 2 to <5 YearsRSVpreF 60 mcg: 5 to <18 Years [Healthy Participants]RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 60 mcg: 2 to <5 Years
RSV A21.9 (14.46 to 33.08)18.6 (13.03 to 26.55)42.8 (23.41 to 78.16)27.7 (17.81 to 42.93)13.9 (8.75 to 22.03)17.7 (9.02 to 34.67)
RSV B24.4 (15.53 to 38.26)16.3 (9.91 to 26.83)39.8 (22.96 to 69.08)34.6 (21.63 to 55.23)17.0 (9.25 to 31.40)20.6 (10.00 to 42.50)
SecondaryMedian Frequencies of RSV F Antigen-Specific Cluster of Differentiation 4 (CD4+) Thymus-Derived Lymphocytes (T) Cells Expressing Interferon (IFN) Gamma and Interleukin-4 (IL-4) Before Vaccination and 1 Month After Vaccination

Median frequencies of RSV F antigen-specific CD4+ T cells expressing IFN gamma and IL-4 before vaccination and 1 month after vaccination were reported in this outcome measure. RSV F enzyme-linked immune absorbent spot assay (ELISpot) limit of detection (LOD) values were IFN gamma = 20 spot forming cell (SFC) per million peripheral blood mononuclear cell (PBMCs) and IL-4 = 4 SFC/million PBMCs. Assay results below LOD=0.5\*LOD for analysis. Frequencies were defined as the count of the RSV F antigen-specific CD4+ T cells and median frequencies were defined as the median of the counts.

Time frame:
Before vaccination and 1 Month after vaccination
Reported as:
Median · SFC/million PBMCs
Median Frequencies of RSV F Antigen-Specific Cluster of Differentiation 4 (CD4+) Thymus-Derived Lymphocytes (T) Cells Expressing Interferon (IFN) Gamma and Interleukin-4 (IL-4) Before Vaccination and 1 Month After Vaccination
SFC/million PBMCsRSVpreF 120 mcg: 5 to <18 Years [Healthy Participants]RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 120 mcg: 2 to <5 YearsRSVpreF 60 mcg: 5 to <18 Years [Healthy Participants]RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 60 mcg: 2 to <5 Years
INF gamma before vaccination47 (10 to 241)60 (10 to 193)10 (10 to 67)53 (10 to 277)41 (10 to 336)10 (10 to 79)
INF gamma 1 month after vaccination255 (10 to 829)293 (10 to 1339)61 (10 to 257)244 (23 to 1027)187 (10 to 780)45 (10 to 184)
IL-4 before vaccination2 (2 to 2)2 (2 to 11)2 (2 to 2)2 (2 to 4)2 (2 to 5)2 (2 to 4)
IL-4 1 month after vaccination2 (2 to 16)4 (2 to 28)2 (2 to 7)2 (2 to 24)2 (2 to 15)2 (2 to 13)

Adverse events

Collected over Local reactions and systemic events: Within 7 days after vaccination. SAEs: Within 6 months post Vaccination and other AEs: Within 1 month post Vaccination. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Healthy RSVpreF 120 Micrograms (mcg)0/25 (0%)0/25 (0%)17/25 (68%)
High Risk RSVpreF 120 mcg0/23 (0%)1/23 (4.3%)15/23 (65.2%)
2 to < 5 Years RSVpreF 120 mcg0/24 (0%)0/24 (0%)9/24 (37.5%)
Healthy RSVpreF 60 mcg0/17 (0%)0/17 (0%)12/17 (70.6%)
High Risk RSVpreF 60 mcg0/18 (0%)1/18 (5.6%)14/18 (77.8%)
2 to < 5 Years RSVpreF 60 mcg0/20 (0%)0/20 (0%)13/20 (65%)
Most frequent serious events
Most frequent serious events
EventHealthy RSVpreF 120 Micrograms (mcg)High Risk RSVpreF 120 mcg2 to < 5 Years RSVpreF 120 mcgHealthy RSVpreF 60 mcgHigh Risk RSVpreF 60 mcg2 to < 5 Years RSVpreF 60 mcg
AsthmaRespiratory, thoracic and mediastinal disorders0/250/230/240/171/180/20
Food allergyImmune system disorders0/251/230/240/170/180/20
Most frequent other events
Showing 10 of 24
Most frequent other events
EventHealthy RSVpreF 120 Micrograms (mcg)High Risk RSVpreF 120 mcg2 to < 5 Years RSVpreF 120 mcgHealthy RSVpreF 60 mcgHigh Risk RSVpreF 60 mcg2 to < 5 Years RSVpreF 60 mcg
Injection site pain (PAIN AT INJECTION SITE)General disorders12/2511/232/247/1710/183/20
Fatigue (FATIGUE)General disorders8/2510/237/248/179/187/20
Headache (HEADACHE)Nervous system disorders7/258/231/247/176/180/20
Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders5/259/230/244/177/180/20
Erythema (REDNESS)Skin and subcutaneous tissue disorders6/252/233/241/172/181/20
Swelling (SWELLING)General disorders3/252/231/241/174/181/20
Injection site painGeneral disorders2/253/230/241/171/180/20
Diarrhoea (DIARRHEA)Gastrointestinal disorders1/252/233/240/171/180/20
Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders2/251/230/240/172/180/20
Pyrexia (FEVER)General disorders0/251/231/241/172/181/20

Baseline characteristics

Safety population included all enrolled participants who received the study intervention.

Age, Customized
Age, Customized(Participants)RSVpreF 120 mcg: 5 to <18 Years [Healthy Participants]RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 120 mcg: 2 to < 5 YearsRSVpreF 60 mcg: 5 to <18 Years [Healthy Participants]RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 60 mcg: 2 to < 5 YearsTotal
Children (2-11 years)9112412122088
Adolescents (12-17 years)1612056039
Sex: Female, Male
Sex: Female, Male(Participants)RSVpreF 120 mcg: 5 to <18 Years [Healthy Participants]RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 120 mcg: 2 to < 5 YearsRSVpreF 60 mcg: 5 to <18 Years [Healthy Participants]RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 60 mcg: 2 to < 5 YearsTotal
Female15111357758
Male10121112111369
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RSVpreF 120 mcg: 5 to <18 Years [Healthy Participants]RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 120 mcg: 2 to < 5 YearsRSVpreF 60 mcg: 5 to <18 Years [Healthy Participants]RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 60 mcg: 2 to < 5 YearsTotal
Hispanic or Latino50134518
Not Hispanic or Latino202322141315107
Unknown or Not Reported0010102
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RSVpreF 120 mcg: 5 to <18 Years [Healthy Participants]RSVpreF 120 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 120 mcg: 2 to < 5 YearsRSVpreF 60 mcg: 5 to <18 Years [Healthy Participants]RSVpreF 60 mcg: 5 to <18 Years [High Risk Participants]RSVpreF 60 mcg: 2 to < 5 YearsTotal
American Indian or Alaska Native0010001
Asian2000002
Native Hawaiian or Other Pacific Islander0000000
Black or African American76326428
White1617171391587
More than one race0032319
Unknown or Not Reported0000000
08

Study locations

17 sites
  • University of Alabama at Birmingham - School of Medicine
    Birmingham, Alabama 35233, United States
  • Stanford University Medical Center
    Palo Alto, California 94304, United States
  • Peninsula Research Associates
    Rolling Hills Estates, California 90274, United States
  • Bio-Medical Research LLC
    Miami, Florida 33144, United States
  • Velocity Clinical Research, Sioux City
    Sioux City, Iowa 51106, United States
  • Velocity Clinical Research, New Orleans
    Metairie, Louisiana 70006, United States
  • Velocity Clinical Research, Omaha
    Omaha, Nebraska 68134, United States
  • Rochester Clinical Research, LLC
    Rochester, New York 14609, United States
  • Duke Vaccine And Trials Unit
    Durham, North Carolina 27703, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Senders Pediatrics
    South Euclid, Ohio 44121, United States
  • Velocity Clinical Research, Providence
    East Greenwich, Rhode Island 02818, United States
  • Innovo Research - Austin Regional Clinic
    Austin, Texas 78726, United States
  • Velocity Clinical Research, Austin
    Austin, Texas 78759, United States
  • Velocity Clinical Research, Salt Lake City
    West Jordan, Utah 84088, United States
  • Seattle Children's - Building Cure
    Seattle, Washington 98101, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Feb 2024, 8 months.

Results were first posted in Mar 2025, 1 year after primary completion.

Of 26 industry-sponsored phase 1 interventional studies under Respiratory Tract Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's 8 months is above that.

Counting every sponsor, half of 35 studies reached it within 8 months; a quarter within 1 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2023
First posted
Jun 12, 2023
StartActual
Jun 22, 2023
Primary completionActual
Feb 29, 2024
CompletionActual
Feb 29, 2024
Results first posted
Mar 6, 2025
Last update
Mar 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05900154
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 12, 2023
Start date
Jun 22, 2023
Primary completion
Feb 29, 2024
Completion
Feb 29, 2024
Results posted
Mar 6, 2025
Last update
Mar 6, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion